From: Tazia Smith
Sent: 4/23/2014 11:54:04 AM
To: jeevacation@gmail.com
CC: • Paul Morris I; Nav Gupta ; Vinit Sahni
J; Vah Stepanian I
Subject: WY and Biotech (C)
Attachments: pic24428.gif; pic23103.gif; pic27254.gif; pic21295.gif; pic14997.gif; 182298_20140422_20140423_1.pdf
Classification: Confidential
Jeffrey -
Just posting you on your biotech basket - earnings a positive catalyst
reversing that downtrend in Gilead. Biogen reported this morning (bottom line
miss, top-line beat), stock has come in from pre-market highs of 5310, now —
$303 (3-day chart below).
Just a reminder that your SY 102.5 call is going to expire 5/1. In speaking
with Nav and vinit, they looked at lot of weaker-yen iterations but their view
is vols are too low and there is an absence of catalysts to present a
compelling trade at this moment to roll into; Nav will email you directly to
highlight entry points on a trade when he sees one. As you know, you've got
your zero-cost option on for some exposure to yen weakness.
(Embedded image moved to file: pic24428.gif)source: Pershing, LLC and
Bloomberg
(Embedded image moved to file: pic23103.gif)
Biogen - 3 -day inter-day chart
(Embedded image moved to file: pic27254.gif)
(Embedded image moved to file: pic21295.gif)
Tazia smith
Director I Key client Partners - us
DB securities Inc
Deutsche Asset & wealth management
345 Park Avenue. 10154-0004 New York, NY, USA
(Embedded image moved to file: pic14997.gif)
CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) DB-SDNY-0 111770
CONFIDENTIAL SDNY_GM_00257954
EFTA01453914